Nektar Therapeutics - Company Profile
Powered by 
All the sales intelligence you need on Nektar Therapeutics in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Nektar Therapeutics fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Nektar Therapeutics.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Nektar Therapeutics (Nektar) is a clinical-stage, research-based drug discovery biopharmaceutical company. It mainly focused on the discovery and development of novel therapies that selectively modulate the immune system to treat autoimmune disorders, chronic inflammatory conditions, and cancer. Nektar's major products include drug candidates such as rezpegaldesleukin, NKTR-0165, which are focused on the treatment of autoimmune diseases, NKTR-0166, uses in the treatment of rheumatology diseases. and NKTR-255 for the treatment of cancer. Nektar collaborates with academic institutions, biotechnology companies, and pharmaceutical corporations to develop and commercialize its therapies. Its research and development involve peptides, small molecule drugs, proteins, antibodies, and other potential biological drug candidates. Nektar is headquartered in San Francisco, California, the US.
Headquarters
United States of America
Address
455 Mission Bay Boulevard South, San Francisco, California, 94158
Website
www.nektar.com
Telephone
1 415 4825300
No of Employees
63
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
NKTR (NASD)
Revenue (2024)
$55.2M
-43.9%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-37.9%
(2024 vs 2023)
Market Cap*
$2.3B
Net Profit Margin (2024)
XYZ
-145.8%
(2024 vs 2023)
* As of and is in US$
Nektar Therapeutics premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Rezpegaldesleukin: Atopic Dermatitis, Alopecia Areata, and Type 1 Diabetes Mellitus |
| NKTR-422: Autoimmune Disorders |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In February, the company entered into a collaboration with the University of California to explore the potential role of TNFR2 agonism in the reduction of neurodegeneration and promotion of neuroprotection. |
| 2025 | Regulatory Approval | In July, the company received a grant from the US Food and Drug Administration for rezpegaldesleukin to treat severe-to-very severe alopecia areata in adults and pediatric patients 12 years of age and older who weigh at least 40 kilograms. |
| 2025 | Contracts/Agreements | In February, the company signed a clinical trial agreement with TrialNet to evaluate Rezpegaldesleukin in patients with new-onset type 1 diabetes mellitus. |
Competitor Comparison
| Key Parameters | Nektar Therapeutics | Eli Lilly and Co | Pfizer Inc | AstraZeneca Plc | Sanofi |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United Kingdom | France |
| City | San Francisco | Indianapolis | New York City | Cambridge | Paris |
| State/Province | California | Indiana | New York | Cambridgeshire | Ile-de-France |
| No. of Employees | 63 | 50,605 | 75,000 | 96,100 | 76,493 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Robert B. Chess | Chairman | Executive Board | 2007 | 69 |
| Howard W. Robin | Chief Executive Officer; Director; President | Executive Board | 2007 | 73 |
| Jason Barnard | Chief Accounting Officer | Senior Management | 2025 | - |
| Robert Bacci | Chief People Officer; Head - Quality & Facilities | Senior Management | - | - |
| Jennifer Ruddock | Chief Business Officer | Senior Management | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer